Brief: Novartis Remibrutinib Delivered Comprehensive Disease Control In Phase III RMS Trials
BRIEF-Novartis Remibrutinib Delivered Comprehensive Disease Control In Phase III RMS Trials Oct 23 (Reuters) - NOVARTIS AG NOVN.S:
NOVARTIS REMIBRUTINIB DELIVERED COMPREHENSIVE DISEASE CONTROL IN PHASE III RMS TRIALS, WITH PROVEN, ROBUST SAFETY PROFILE
REMIBRUTINIB ACHIEVED SIGNIFICANT AND CLINICALLY MEANINGFUL REDUCTION IN RELAPSES VERSUS TERIFLUNOMIDE
MRI DISEASE ACTIVITY SIGNIFICANTLY REDUCED WITH REMIBRUTINIB VERSUS. TERIFLUNOMIDE IN TWO TRIALS
OVER 92% OF REMIBRUTINIB PATIENTS REMAINED FREE FROM DISEASE PROGRESSION AS ASSESSED BY 6-MONTH CDP IN PHASE III RMS TRIALS
IN ADDITION TO EFFICACY FINDINGS, REMIBRUTINIB DEMONSTRATED NO LIVER SAFETY SIGNAL, INCLUDING NO HY'S LAW CASES
REMIBRUTINIB CUTS ANNUALIZED RELAPSE RATE BY 35.2% AND 31.2% VERSUS TERIFLUNOMIDE IN REMODEL-1 AND REMODEL-2 TRIALS
REMIBRUTINIB DEMONSTRATED SUPERIORITY VERSUS TERIFLUNOMIDE ON ALL KEY SECONDARY ENDPOINTS WITHIN EACH TRIAL
Source text: ID:nGNE5D222j
Further company coverage: NOVN.S
(Gdansk Newsroom)
((((gdansk.newsroom@thomsonreuters.com ; +48 587785269; ));;))
Recent news on Novartis AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Novartis Remibrutinib Delivered Comprehensive Disease Control In Phase III RMS Trials
Bristol Myers discloses patient death in early-stage cell therapy study (updated)
Novartis' breast cancer drug cuts risk of death by 19% after six years, data shows
Novartis AG expected to post earnings of $2.27 a share - Earnings Preview